4Q PREVIEW: Investors await details on Gilead's hepatitis C drug launch, outlook
This article was originally published in Scrip
Executive Summary
Gilead Sciences is expected to provide a first official look at the very early launch of the hepatitis C drug Sovaldi when it announces fourth-quarter results.